[Federal Register Volume 82, Number 51 (Friday, March 17, 2017)]
[Notices]
[Page 14212]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-05347]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting; Amendment

AGENCY: Assistant Secretary of Defense (Health Affairs), Department of 
Defense.

ACTION: Notice of meeting; amendment.

-----------------------------------------------------------------------

SUMMARY: On Wednesday, February 15, 2017 (82 FR 10762), the Department 
of Defense published a notice announcing a Federal Advisory Committee 
Meeting of the Uniform Formulary Beneficiary Advisory Panel. Subsequent 
to the publication of the notice, an item was added to the Meeting 
Agenda. All other information in the February 15, 2017 notice remains 
the same.

DATES: Wednesday, March 22, 2017, from 9:00 a.m. to 12:00 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CAPT Edward Norton, DFO, Uniform 
Formulary Beneficiary Advisory Panel, 7700 Arlington Boulevard, Suite 
5101, Falls Church, VA 22042-5101. Telephone: (703) 681-2890. Fax: 
(703) 681-1940. Email Address: [email protected].

SUPPLEMENTARY INFORMATION: Due to circumstances beyond the control of 
the Designated Federal Officer and the Department of Defense, the 
Uniform Formulary Beneficiary Advisory Panel was unable to provide 
public notification concerning a change to a previously announced 
meeting agenda for a meeting on March 22, 2017, of the Uniform 
Formulary Beneficiary Advisory Panel as required by 41 CFR 102-
3.150(a). Accordingly, the Advisory Committee Management Officer for 
the Department of Defense, pursuant to 41 CFR 102-3.150(b), waives the 
15-calendar day notification requirement.
    This meeting is being held under the provisions of the Federal 
Advisory Committee Act (FACA) of 1972 (5 U.S.C., Appendix, as amended), 
the Government in the Sunshine Act of 1976 (5 U.S.C. 552b, as amended), 
and 41 CFR 102-3.140.
    Under the provisions of the Federal Advisory Committee Act of 1972 
(5 U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 CFR 102-3.150, the Department 
of Defense announces that an item in the Meeting Agenda has changed.
    The revised Meeting Agenda reads as follows:

Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Public Citizen Comments
4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Hepatitis C Agents--Direct Acting Antivirals
    b. Antibiotics--Tetracyclines
    c. Proton Pump Inhibitors
5. Recently Approved Drugs Review
6. Pertinent Utilization Management Issues
7. Panel Discussions and Vote

    Dated: March 13, 2017.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2017-05347 Filed 3-16-17; 8:45 am]
 BILLING CODE 5001-06-P